RU96111418A - DERIVATIVES OF PYRIMIDINDION, PYRIMIDINTRION, TRIAZINDION, TETRAHYDROCHINAZOLINDION AS ANTAGONISTS α1 ADRENERGIC RECEPTORS - Google Patents
DERIVATIVES OF PYRIMIDINDION, PYRIMIDINTRION, TRIAZINDION, TETRAHYDROCHINAZOLINDION AS ANTAGONISTS α1 ADRENERGIC RECEPTORSInfo
- Publication number
- RU96111418A RU96111418A RU96111418/04A RU96111418A RU96111418A RU 96111418 A RU96111418 A RU 96111418A RU 96111418/04 A RU96111418/04 A RU 96111418/04A RU 96111418 A RU96111418 A RU 96111418A RU 96111418 A RU96111418 A RU 96111418A
- Authority
- RU
- Russia
- Prior art keywords
- denotes
- alkyl
- hydrogen
- methyl
- formula
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title claims 2
- 102000030014 alpha-1 adrenergic receptor family Human genes 0.000 title 1
- 108020004102 alpha-1 adrenergic receptor family Proteins 0.000 title 1
- 230000003042 antagnostic Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- SOFSSZFBVOGIKD-UHFFFAOYSA-N pyrimidine-2,4,5-trione Chemical compound O=C1NC(=O)C(=O)C=N1 SOFSSZFBVOGIKD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- -1 acetylamino, amino Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000005418 aryl aryl group Chemical group 0.000 claims 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 4
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 claims 3
- 238000005804 alkylation reaction Methods 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 210000001635 Urinary Tract Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- CORCKSPJYGOTDH-UHFFFAOYSA-N 3-[3-[4-[4-fluoro-2-(1,3-oxazol-2-yl)phenyl]piperazin-1-yl]propyl]-5-methyl-1H-pyrimidine-2,4-dione Chemical compound O=C1C(C)=CNC(=O)N1CCCN1CCN(C=2C(=CC(F)=CC=2)C=2OC=CN=2)CC1 CORCKSPJYGOTDH-UHFFFAOYSA-N 0.000 claims 1
- SDHKUGRGWQZRIK-UHFFFAOYSA-N 3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-(hydroxymethyl)-1H-pyrimidine-2,4-dione Chemical compound O=C1C(CO)=CNC(=O)N1CCCN1CCN(C=2C(=CC(F)=CC=2)OCC(F)(F)F)CC1 SDHKUGRGWQZRIK-UHFFFAOYSA-N 0.000 claims 1
- WEZFJPKJUIGDPS-UHFFFAOYSA-N 3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-1H-pyrimidine-2,4-dione Chemical compound O=C1C(C)=CNC(=O)N1CCCN1CCN(C=2C(=CC(F)=CC=2)OCC(F)(F)F)CC1 WEZFJPKJUIGDPS-UHFFFAOYSA-N 0.000 claims 1
- AXOUSXBEKHBGLU-UHFFFAOYSA-N 5-ethyl-3-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1H-pyrimidine-2,4-dione Chemical compound O=C1C(CC)=CNC(=O)N1CCCN1CCN(C=2C(=CC(F)=CC=2)OCC(F)(F)F)CC1 AXOUSXBEKHBGLU-UHFFFAOYSA-N 0.000 claims 1
- RCOBWVAGWYRNHZ-UHFFFAOYSA-N 5-methyl-3-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1H-pyrimidine-2,4-dione Chemical compound O=C1C(C)=CNC(=O)N1CCCN1CCN(C=2C(=CC=CC=2)OCC(F)(F)F)CC1 RCOBWVAGWYRNHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N HCl HCl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 238000006264 debenzylation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 230000001681 protective Effects 0.000 claims 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Claims (23)
где R1 обозначает ацетиламино, амино, циано, трифторацетиламино, галоген, водород, гидрокси, нитро, метилсульфониламино, 2-пропинилокси, группу, выбранную из C1-C6алкила, C3-C6циклоалкила, C3-C6циклоалкилC1-C4алкила, C1-C6алкилокси, C3-C6циклоалкилокси, C3-C6циклоалкилC1-C4алкилокси и C1-C4алкилтио (причем указанная группа, кроме того, необязательно замещена одним-тремя атомами галогена), или группу, выбранную из арила, арилC1-C4алкила, гетероарила, гетероарилC1-C4алкила, арилокси, арилC1-C4алкилокси, гетероарилокси и гетероарилC1-C4алкилокси (причем указанные арил и гетероарил, кроме того, необязательно замещены одним-двумя радикалами, независимо выбранными из галогена и циано);
R2 обозначает циано, галоген, водород, гидрокси или группу, выбранную из C1-C6алкила и C1-C6алкилокси (причем указанная группа, кроме того, необязательно замещена одним-тремя атомами галогена);
R3 и R4 каждый обозначает водород или метил или вместе обозначают этилен; и
R5 обозначает группу, выбранную из формул (а), (b), (c) и (d):
в которых Х обозначает С(О), СН2 или CH(OH);
Y обозначает CH2 или СН(ОН);
Z обозначает N или C(R9), где R9 обозначает водород, C1-C6алкил или гидрокси;
R6 обозначает водород, группу, выбранную из C1-C6алкила, C3-C6циклоалкила, C3-C6циклоалкилC1-C4алкила (причем указанная группа, кроме того, необязательно замещена одним-тремя атомами галогена), или группу, выбранную из арила, гетероарила, арилC1-C4алкила и гетероарилC1-C4алкила (причем указанные арил и гетероарил, кроме того, необязательно замещены одним-тремя радикалами, выбранными из галогена, циано, C1-C6алкилокси, C1-C6алкила и арила);
R7 обозначает C1-C6алканоил, карбамоил, циано, диC1-C6алкиламино, галоген, водород, гидрокси, гидроксииминометил, C1-C6алкилсульфонил, C1-C6алкилтио, группу, выбранную из C1-C6алкила, C3-C6циклоалкила, C1-C6алкилокси и C1-C6алкилоксиC1-C4алкила (причем указанная группа, кроме того, необязательно замещена одним-тремя радикалами, выбранными из галогена, гидрокси или C1-C6алкилокси), или группу, выбранную из арила, гетероарила, арилC1-C4алкила и гетероарилC1-C4алкила (причем указанный арил и гетероарил, кроме того, необязательно замещены одним-тремя радикалами, выбранными из галогена, циано, C1-C6алкилокси, C1-C6алкила и арила), или R7 и R9 вместе обозначают тетраметилен; и каждый R8 независимо обозначает водород, гидрокси, метил или этил; и его фармацевтически приемлемые соли и N-оксиды.1. The compound of formula I
where R 1 denotes acetylamino, amino, cyano, trifluoroacetylamino, halogen, hydrogen, hydroxy, nitro, methylsulfonylamino, 2-propynyloxy, a group selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkylC 1 -C 4 alkyl, C 1 -C 6 alkyloxy, C 3 -C 6 cycloalkyloxy, C 3 -C 6 cycloalkyl C 1 -C 4 alkyloxy and C 1 -C 4 alkylthio (moreover, this group is, in addition, optionally substituted with one- three halo atoms) or a group selected from aryl, arilC 1 -C 4 alkyl, heteroaryl, geteroarilC 1 -C 4 alkyl, aryloxy, arilC 1 -C 4 alkyloxy, heteroaryloxy and geteroarilC 1 -C 4 alkilo B (which aryl and heteroaryl are further optionally substituted by one or two radicals independently selected from halo and cyano);
R 2 is cyano, halogen, hydrogen, hydroxy, or a group selected from C 1 -C 6 alkyl and C 1 -C 6 alkyloxy (and this group is also optionally substituted with one to three halogen atoms);
R 3 and R 4 each denotes hydrogen or methyl or together represent ethylene; and
R 5 denotes a group selected from formulas (a), (b), (c) and (d):
in which X represents C (O), CH 2 or CH (OH);
Y represents CH 2 or CH (OH);
Z is N or C (R 9 ), where R 9 is hydrogen, C 1 -C 6 alkyl or hydroxy;
R 6 denotes hydrogen, a group selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkyl C 1 -C 4 alkyl (and this group, in addition, optionally substituted by one to three halogen atoms) or a group selected from aryl, heteroaryl, arylC 1 -C 4 alkyl and heteroaryl C 1 -C 4 alkyl (moreover, said aryl and heteroaryl, in addition, are optionally substituted with one to three radicals selected from halogen, cyano, C 1 -C 6 alkyloxy, C 1 -C 6 alkyl and aryl);
R 7 is C 1 -C 6 alkanoyl, carbamoyl, cyano, diC 1 -C 6 alkylamino, halogen, hydrogen, hydroxy, hydroxyiminomethyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylthio, a group selected from C 1 - C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkyloxy and C 1 -C 6 alkyloxyC 1 -C 4 alkyl (and this group is also optionally substituted with one to three radicals selected from halogen, hydroxy or C 1 -C 6 alkyloxy) or a group selected from aryl, heteroaryl, arilC 1 -C 4 alkyl and geteroarilC 1 -C 4 alkyl (which aryl and heteroaryl are further optionally substituted with one to three radicals selected from halogen, cyano, C 1 -C 6 alkyloxy, C 1 -C 6 alkyl and aryl), or R 7 and R 9 together represent tetramethylene; and each R 8 is independently hydrogen, hydroxy, methyl, or ethyl; and its pharmaceutically acceptable salts and N-oxides.
где каждый из радикалов R1, R2, R3, R4 и R5 имеет значение, указанное в п. 1, и его фармацевтически приемлемых солей и N-оксидов, включающий: (а) алкилирование соединения формулы 3
или его защищенного производного, где L обозначает отщепляемую группу и каждый радикал R3, R4 и R5 имеет значение, указанное в п.1 для формулы I, соединением формулы 2
или его защищенным производным, где каждый из R1 и R2 имеет значение, указанное в п. 1 для формулы I, и при необходимости последующее удаление защитной группы; или (б) алкилирование соединения формулы H-R5, где R5 имеет значение, указанное в п.1, соединением формулы 5
где L обозначает отщеляемую группу и каждй из R1, R2, R3 и R4 имеет значение, указанное в п. 1 для формулы I; и (в) необязательно последующее дебензилирование соединения формулы I, где R6 обозначает бензил, для получения соединения формулы I, где R6 обозначает водород; (г) необязательно последующее алкилирование соединения формулы I, где R6 обозначает водород, для получения соединения формулы I, где R6 обозначает C1 - C6 алкил, C3 - C6циклоалкил, C3 - C6 циклоалкилC1 - C4алкил и группу, выбранную из арила, гетероарила, арил C1-C4 алкила и гетероарилC1 - C4алкила (причем указанные арил и гетероарил, кроме того, необязательно замещены одним-тремя радикалами, выбранными из галогена, циано, C1 - C6алкилокси, C1 - C6алкила и арила); (д) необязательно последующее окисление соединения формулы I для получения N-оксидного производного; (е) необязательно последующее восстановление N-оксидного производного соединения формулы I до неокисленной формы; (ж) необязательно последующее превращение соединения формулы I в фармацевтически приемлемую соль; и (з) необязательно последующее превращение соединения формулы I в виде соли в несолевую форму.19. The method of obtaining the compounds of formula I:
where each of the radicals R 1 , R 2 , R 3 , R 4 and R 5 has the meaning given in paragraph 1, and its pharmaceutically acceptable salts and N-oxides, including: (a) the alkylation of compounds of formula 3
or a protected derivative thereof, where L denotes a leaving group and each of the radicals R 3 , R 4 and R 5 has the meaning given in claim 1 for formula I, a compound of formula 2
or its protected derivative, where each of R 1 and R 2 has the meaning given in paragraph 1 for formula I, and, if necessary, the subsequent removal of the protective group; or (b) alkylation of a compound of formula HR 5 , where R 5 has the meaning given in claim 1, a compound of formula 5
where L denotes a breakaway group and each of R 1 , R 2 , R 3 and R 4 is as defined in claim 1 for formula I; and (c) optionally subsequent debenzylation of a compound of formula I, where R 6 is benzyl, to produce a compound of formula I, where R 6 is hydrogen; (d) optionally subsequent alkylation of a compound of formula I, where R 6 is hydrogen, to produce a compound of formula I, where R 6 is C 1 - C 6 alkyl, C 3 - C 6 cycloalkyl, C 3 - C 6 cycloalkyl C 1 - C 4 alkyl and a group selected from aryl, heteroaryl, aryl C 1 -C 4 alkyl and geteroarilC 1 - C 4 alkyl (which aryl and heteroaryl are further optionally substituted with one to three radicals selected from halo, cyano, C 1 - C 6 alkyloxy, C 1 - C 6 alkyl and aryl); (e) optionally, subsequent oxidation of the compound of formula I to form an N-oxide derivative; (e) optionally, subsequent reduction of the N-oxide derivative of the compound of formula I to the non-oxidized form; (g) optionally, the subsequent conversion of the compound of formula I to a pharmaceutically acceptable salt; and (h) optionally, the subsequent conversion of the compound of formula I as a salt to a non-salt form.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48918395A | 1995-06-09 | 1995-06-09 | |
US489.183 | 1995-06-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96111418A true RU96111418A (en) | 1998-09-27 |
RU2175322C2 RU2175322C2 (en) | 2001-10-27 |
Family
ID=23942748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96111418/04A RU2175322C2 (en) | 1995-06-09 | 1996-06-07 | DERIVATIVES OF PYRIMIDINEDIONE, TRIAZINEDIONE, TETRAHYDRO- -QUINAZOLINEDIONE AS ANTAGONISTS OF α1-ADRENOCEPTORS, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0748800B1 (en) |
JP (1) | JP2721147B2 (en) |
KR (1) | KR100446877B1 (en) |
CN (1) | CN1118459C (en) |
AR (1) | AR003428A1 (en) |
AT (1) | ATE201016T1 (en) |
AU (1) | AU710754B2 (en) |
BR (1) | BR9602705A (en) |
CA (1) | CA2178548A1 (en) |
CO (1) | CO4700472A1 (en) |
CZ (1) | CZ290004B6 (en) |
DE (1) | DE69612698T2 (en) |
DK (1) | DK0748800T3 (en) |
ES (1) | ES2157366T3 (en) |
GR (1) | GR3036307T3 (en) |
HK (1) | HK1013065A1 (en) |
HU (1) | HU223594B1 (en) |
IL (1) | IL118519A (en) |
MA (1) | MA23899A1 (en) |
MY (1) | MY113499A (en) |
NO (1) | NO309424B1 (en) |
NZ (1) | NZ286720A (en) |
PE (1) | PE46497A1 (en) |
PL (1) | PL188061B1 (en) |
PT (1) | PT748800E (en) |
RU (1) | RU2175322C2 (en) |
SA (1) | SA96170263B1 (en) |
SG (1) | SG45486A1 (en) |
TR (1) | TR970073A2 (en) |
TW (1) | TW340846B (en) |
UY (1) | UY24257A1 (en) |
ZA (1) | ZA964561B (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271234B1 (en) | 1997-08-01 | 2001-08-07 | Recordati S.A., Chemical And Pharmaceutical Company | 1,4-disubstituted piperazines |
CN1157376C (en) | 1997-10-31 | 2004-07-14 | 第一三得利制药株式会社 | Arylpiperidinopropanol and arylpiperaznipropanol derivatives and pharmaceuticals containing the same |
US6083950A (en) * | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
ATE325104T1 (en) * | 1998-03-30 | 2006-06-15 | Hoffmann La Roche | METHOD FOR FABRICATION OF ALPHA 1L ADRENORECEPTOR ANTAGONISTS |
AU1979799A (en) * | 1998-07-21 | 2000-02-14 | Ranbaxy Laboratories Limited | Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers |
MXPA01000637A (en) * | 1998-07-21 | 2002-04-08 | Ranbaxy Lab Ltd | Arylpiperazine derivatives useful as uroselective alpha1-adrenoceptor blockers. |
WO2000029386A1 (en) | 1998-11-12 | 2000-05-25 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
US6387909B1 (en) | 1999-07-30 | 2002-05-14 | Recordati S.A. Chemical And Pharmaceutical Company | Thienopyranecarboxamide derivatives |
US6306861B1 (en) | 1999-07-30 | 2001-10-23 | Recordati S.A. Chemical And Pharmaceutical Company | Thienopyrancecarboxamide derivatives |
GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
US6403594B1 (en) | 1999-10-18 | 2002-06-11 | Recordati, S.A. Chemical And Pharmaceutical Company | Benzopyran derivatives |
US6365591B1 (en) | 1999-10-18 | 2002-04-02 | Recordati, S.A., Chemical And Pharmacueticals Company | Isoxazolecarboxamide derivatives |
JP4931314B2 (en) * | 2000-01-25 | 2012-05-16 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Gonadotropin releasing hormone receptor antagonist and related methods |
KR20030068164A (en) * | 2000-11-30 | 2003-08-19 | 랜박시 래보러터리스 리미티드 | 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE α1-ADRENOCEPTOR BLOCKERS |
WO2003011841A1 (en) | 2001-08-02 | 2003-02-13 | Neurocrine Biosciences, Inc. | 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
DE10311065A1 (en) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | New 1-(cyclic amino-alkyl)-pyrimidin-2(1H)-one derivatives, are selective dopamine D3 receptor ligands useful for treating CNS disorders, especially schizophrenia or depression |
US20040242566A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
CN1867560A (en) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors |
EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
MY140489A (en) * | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
CN102127053A (en) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
EP1655288A1 (en) * | 2004-11-05 | 2006-05-10 | Institut Pasteur | Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents |
CA2591757C (en) | 2004-12-20 | 2014-03-25 | Makoto Kotake | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
EP2805953B1 (en) | 2004-12-21 | 2016-03-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1889827B1 (en) * | 2005-05-25 | 2010-08-25 | Eisai R&D Management Co., Ltd. | Process for producing [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
ME02005B (en) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Dipeptidyl peptidase inhibitors for treating diabetes |
CA2622642C (en) * | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
DE102008030091B4 (en) * | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracil derivatives and their use |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
RU2449994C1 (en) * | 2011-03-10 | 2012-05-10 | Светлана Алексеевна Мещерякова | 6-(4-benzylpiperazino)-1,3-dimethyluracyl dihydrochloride showing biological activity |
JP6039587B2 (en) * | 2011-03-18 | 2016-12-07 | コーセプト セラピューティクス, インコーポレイテッド | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
GB201318886D0 (en) * | 2013-10-25 | 2013-12-11 | Givaudan Sa | Improvements i or relating to organic compounds |
SG10201913878YA (en) | 2016-03-17 | 2020-03-30 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
CA3157658A1 (en) * | 2019-10-28 | 2021-05-06 | Nippon Soda Co., Ltd. | 2,6-dioxo-3,6-dihydropyrimidine compound, agricultural and horticultural bactericide, nematicide, and medical and veterinary antifungal agent |
JPWO2022230804A1 (en) * | 2021-04-28 | 2022-11-03 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2727469A1 (en) * | 1977-06-18 | 1978-12-21 | Hoechst Ag | NEW HEXAHYDROPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
JPH02184667A (en) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | N-n'-di-substituted piperazyl derivative and dysuria-improving agent containing the same |
JPH0344379A (en) * | 1989-07-13 | 1991-02-26 | Yamasa Shoyu Co Ltd | N3-piperazinouracil derivative |
JP2814600B2 (en) * | 1989-08-31 | 1998-10-22 | 正幸 石川 | Drugs for dysuria |
EP0558245A1 (en) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors |
FR2727682A1 (en) * | 1994-12-02 | 1996-06-07 | Pf Medicament | NOVEL DERIVATIVES OF 3,5-DIOXO- (2H, 4H) -1,2,4-TRIAZINES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT |
-
1996
- 1996-05-28 DK DK96108493T patent/DK0748800T3/en active
- 1996-05-28 AT AT96108493T patent/ATE201016T1/en not_active IP Right Cessation
- 1996-05-28 DE DE69612698T patent/DE69612698T2/en not_active Expired - Fee Related
- 1996-05-28 EP EP96108493A patent/EP0748800B1/en not_active Expired - Lifetime
- 1996-05-28 PT PT96108493T patent/PT748800E/en unknown
- 1996-05-28 ES ES96108493T patent/ES2157366T3/en not_active Expired - Lifetime
- 1996-05-31 IL IL11851996A patent/IL118519A/en not_active IP Right Cessation
- 1996-06-03 AU AU54690/96A patent/AU710754B2/en not_active Ceased
- 1996-06-03 ZA ZA964561A patent/ZA964561B/en unknown
- 1996-06-04 NZ NZ286720A patent/NZ286720A/en unknown
- 1996-06-05 HU HU9601529A patent/HU223594B1/en not_active IP Right Cessation
- 1996-06-05 PL PL96314635A patent/PL188061B1/en not_active IP Right Cessation
- 1996-06-06 MA MA24270A patent/MA23899A1/en unknown
- 1996-06-06 TR TR96/00475A patent/TR970073A2/en unknown
- 1996-06-06 PE PE1996000428A patent/PE46497A1/en not_active Application Discontinuation
- 1996-06-06 AR ARP960103000A patent/AR003428A1/en active IP Right Grant
- 1996-06-07 UY UY24257A patent/UY24257A1/en not_active IP Right Cessation
- 1996-06-07 NO NO962412A patent/NO309424B1/en unknown
- 1996-06-07 RU RU96111418/04A patent/RU2175322C2/en not_active IP Right Cessation
- 1996-06-07 BR BR9602705A patent/BR9602705A/en not_active IP Right Cessation
- 1996-06-07 MY MYPI96002314A patent/MY113499A/en unknown
- 1996-06-07 CN CN96110490A patent/CN1118459C/en not_active Expired - Fee Related
- 1996-06-07 CO CO96029677A patent/CO4700472A1/en unknown
- 1996-06-07 CA CA002178548A patent/CA2178548A1/en not_active Abandoned
- 1996-06-07 JP JP8145236A patent/JP2721147B2/en not_active Expired - Fee Related
- 1996-06-07 SG SG1996010018A patent/SG45486A1/en unknown
- 1996-06-08 KR KR1019960020447A patent/KR100446877B1/en not_active IP Right Cessation
- 1996-06-10 CZ CZ19961696A patent/CZ290004B6/en not_active IP Right Cessation
- 1996-07-11 TW TW085108416A patent/TW340846B/en active
- 1996-08-26 SA SA96170263A patent/SA96170263B1/en unknown
-
1998
- 1998-12-21 HK HK98114167A patent/HK1013065A1/en not_active IP Right Cessation
-
2001
- 2001-07-31 GR GR20010401157T patent/GR3036307T3/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96111418A (en) | DERIVATIVES OF PYRIMIDINDION, PYRIMIDINTRION, TRIAZINDION, TETRAHYDROCHINAZOLINDION AS ANTAGONISTS α1 ADRENERGIC RECEPTORS | |
KR970001344A (en) | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolindione derivatives as α-adrenergic receptor antagonists | |
JP5198256B2 (en) | Fused heterocyclic compounds, and compositions and uses thereof | |
CA2748864C (en) | Amino-heterocyclic compounds used as pde9 inhibitors | |
TWI634109B (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
JP2020524719A5 (en) | ||
AU782191B2 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
JP2008533020A (en) | Quinazolinone T-type calcium channel antagonist | |
JP6427506B2 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
JP4915715B2 (en) | Phenylpyridazine derivative and pharmaceutical containing the same | |
RU2350616C2 (en) | Pyrazole- and imidazopyrimidine derivatives | |
JPH0314563A (en) | Novel 4-fluorobenzoic acid derivative | |
RU98114683A (en) | 5-H-THIAZOLE [3,2-A] PYRIMIDINE DERIVATIVES | |
SK173397A3 (en) | Aromatic compounds and pharmaceutical compositions containing them | |
RU2001133456A (en) | 5-phenylpyrimidine derivatives | |
TW201625581A (en) | Oxo-heterocyclic derivatives | |
WO2017043636A1 (en) | Novel benzimidazole compound and pharmaceutical use of same | |
JP2021080266A (en) | USE OF MORPHINAN DERIVATIVE FOR TREATMENT OF OPIOID δ RECEPTOR AGONIST-RELATED DISEASE | |
JPH05194441A (en) | New substituted 3-piperazinylalkyl-2,3-dihydro-4h- 1,3-benzoxazin-4-one, its production and its use for medical treatment | |
RU2003117481A (en) | Pyrimidine derivatives | |
WO2018168894A1 (en) | Deuterated benzimidazole compound and medicinal use thereof | |
RU2804319C2 (en) | Deuterized benzimidazole compound and its medical use | |
RU2003113966A (en) | SUBSTITUTED 3,4-DIHYDROPYRIDO [1,2-A] PYRIMIDINES | |
CA2461806A1 (en) | Water-soluble phenylpyridazine derivatives and medicines containing the same | |
JP2001302648A5 (en) |